Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Genetic variant in SPDL1 reveals novel mechanism linking pulmonary fibrosis risk and cancer protection

View ORCID ProfileJukka T. Koskela, View ORCID ProfilePaavo Häppölä, Aoxing Liu, FinnGen, View ORCID ProfileJuulia Partanen, Giulio Genovese, Mykyta Artomov, Mikko N.M. Myllymäki, Masahiro Kanai, Wei Zhou, Juha M. Karjalainen, Teemu Palviainen, Justiina Ronkainen, Sylvain Sebert, Taru Tukiainen, Priit Palta, Jaakko Kaprio, Mitja Kurki, Andrea Ganna, Aarno Palotie, Tarja Laitinen, Marjukka Myllärniemi, Mark J. Daly
doi: https://doi.org/10.1101/2021.05.07.21255988
Jukka T. Koskela
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
2Medical and Population Genetics, Broad Institute, Cambridge, MA, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jukka T. Koskela
  • For correspondence: mark.daly{at}helsinki.fi jukka.koskela{at}helsinki.fi
Paavo Häppölä
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paavo Häppölä
Aoxing Liu
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juulia Partanen
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Juulia Partanen
Giulio Genovese
3Stanley Center, Broad Institute of Harvard and MIT, Cambridge, MA, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mykyta Artomov
2Medical and Population Genetics, Broad Institute, Cambridge, MA, United States of America
7Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikko N.M. Myllymäki
4Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, 00290, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiro Kanai
2Medical and Population Genetics, Broad Institute, Cambridge, MA, United States of America
7Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Zhou
5Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA
6Center for Statistical Genetics, University of Michigan School of Public Health, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juha M. Karjalainen
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
2Medical and Population Genetics, Broad Institute, Cambridge, MA, United States of America
7Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teemu Palviainen
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justiina Ronkainen
8Center for Life Course Health Research, University of Oulu, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvain Sebert
8Center for Life Course Health Research, University of Oulu, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taru Tukiainen
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priit Palta
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaakko Kaprio
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitja Kurki
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
2Medical and Population Genetics, Broad Institute, Cambridge, MA, United States of America
7Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Ganna
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aarno Palotie
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
2Medical and Population Genetics, Broad Institute, Cambridge, MA, United States of America
3Stanley Center, Broad Institute of Harvard and MIT, Cambridge, MA, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tarja Laitinen
9Administration Center, Tampere University Hospital, Tampere, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marjukka Myllärniemi
10University of Helsinki and Helsinki University Hospital, Heart and Lung Center, Department of Pulmonary Medicine, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. Daly
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
2Medical and Population Genetics, Broad Institute, Cambridge, MA, United States of America
7Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mark.daly{at}helsinki.fi jukka.koskela{at}helsinki.fi
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Idiopathic Pulmonary Fibrosis (IPF) is a rare disease with poor prognosis. By contrast, cancer is common in any elderly population and a leading killer, but is now often curable. Of note, whereas IPF is driven by cellular senescence, cancer is characterized by uncontrolled cell division.

Using data available from two large biobank-based studies (Finnish FinnGen study and UK biobank), we conducted a comprehensive analysis of the shared genetic background of IPF and cancer. In a population sample of 218,792 Finns with complete longitudinal health histories, we estimated the effect of individual genetic variants to the lifetime risk of IPF and cancer. We extend the analysis from IPF-GWAS to pan-cancer meta-analysis over FinnGen and UK Biobank and finally to the identification of genetic drivers of somatic chromosomal alterations.

We detected six loci (SPDL1, MAD1L1, MAP2K1, RTEL1-STMN3, TERC-ACTRT3, OBFC1) associated with both IPF and cancer, all closely related to cellular division. However, each individual signal is found with opposite effects over the two diseases, termed as antagonistic pleiotropy. Several of these loci (TERC-ACTRT3, RTEL1-STMN3, OBFC1) are among the strongest inherited factors for constitutive telomere length variation and consistently indicate that shorter telomere length would increase the risk for IPF but protect from malignancy. However, a Finnish enriched SPDL1 missense variant and a common MAD1L1 intronic variant had no effect on telomere length but were shown to protect individuals from accumulation of somatic mutations.

The decreased risk of cancer in SPDL1 and MAD1L1 variant carriers might result from a lower number of chromosomal alterations accumulated over time, conversely leading to fibrosis in the lung due to cellular senescence-induced inflammation. We hypothesize that the SPDL1 missense variant functions as gain-of-function mutation, leading to cellular senescence, a barrier to cancer and a driver of fibrosis in IPF. If translated to therapy, these findings might not only be able to offer relief to individuals with IPF, but also to protect from onset of cancer.

Competing Interest Statement

JTK, AP and MJD are members of the Pfizer Finland FinnGen Advisory Board. MJD is a founder of Maze Therapeutics. Other co-authors report no conflicts of interest.

Funding Statement

Jukka T. Koskela, Aarno Palotie, Mark J. Daly and Jaakko Kaprio have been funded by the Academy of Finland. Taru Tukiainen has funding from Academy of Finland, Sigrid Juselius Foundation and University of Helsinki. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and by twelve industry partners (AbbVie Inc, AstraZeneca UK Ltd, Biogen MA Inc, Celgene Corporation, Celgene International II Sarl, Genentech Inc, Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc and Novartis AG). The funding sources had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The patients and control subjects in FinnGen provided their informed consent for biobank research based on the Finnish Biobank Act. Alternatively, older research cohorts, collected prior the start of FinnGen (in August 2017), were collected based on study-specific consent and later transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority for Welfare and Health. The recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen study is approved by the Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, THL/1524/5.05.00/2020, and THL/2364/14.02/2020), Digital and Population Data Service Agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: Kela 58/522/2017, Kela 131/522/2018, Kela 70/522/2019, Kela 98/522/2019, Kela 138/522/2019, Kela 2/522/2020, Kela 16/522/2020), and Statistics Finland (permit numbers: TK-53-1041-17 and TK-53-90-20). The Biobank Access Decisions for FinnGen samples and the data utilized in FinnGen Data Freeze 6 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

FinnGen summary level results (summary statistics genome-wide association analysis and data at the phenotype level, including endpoint definitions, statistics about number of individuals, gender distribution, and longitudinal relationships) are made freely available every 6 month. The latest freely available data release IV consists of 176,899 participants.

https://finngen.gitbook.io/documentation/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted May 10, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Genetic variant in SPDL1 reveals novel mechanism linking pulmonary fibrosis risk and cancer protection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Genetic variant in SPDL1 reveals novel mechanism linking pulmonary fibrosis risk and cancer protection
Jukka T. Koskela, Paavo Häppölä, Aoxing Liu, FinnGen, Juulia Partanen, Giulio Genovese, Mykyta Artomov, Mikko N.M. Myllymäki, Masahiro Kanai, Wei Zhou, Juha M. Karjalainen, Teemu Palviainen, Justiina Ronkainen, Sylvain Sebert, Taru Tukiainen, Priit Palta, Jaakko Kaprio, Mitja Kurki, Andrea Ganna, Aarno Palotie, Tarja Laitinen, Marjukka Myllärniemi, Mark J. Daly
medRxiv 2021.05.07.21255988; doi: https://doi.org/10.1101/2021.05.07.21255988
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Genetic variant in SPDL1 reveals novel mechanism linking pulmonary fibrosis risk and cancer protection
Jukka T. Koskela, Paavo Häppölä, Aoxing Liu, FinnGen, Juulia Partanen, Giulio Genovese, Mykyta Artomov, Mikko N.M. Myllymäki, Masahiro Kanai, Wei Zhou, Juha M. Karjalainen, Teemu Palviainen, Justiina Ronkainen, Sylvain Sebert, Taru Tukiainen, Priit Palta, Jaakko Kaprio, Mitja Kurki, Andrea Ganna, Aarno Palotie, Tarja Laitinen, Marjukka Myllärniemi, Mark J. Daly
medRxiv 2021.05.07.21255988; doi: https://doi.org/10.1101/2021.05.07.21255988

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (760)
  • Anesthesia (222)
  • Cardiovascular Medicine (3316)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (480)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13403)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5182)
  • Geriatric Medicine (483)
  • Health Economics (786)
  • Health Informatics (3286)
  • Health Policy (1146)
  • Health Systems and Quality Improvement (1199)
  • Hematology (432)
  • HIV/AIDS (1024)
  • Infectious Diseases (except HIV/AIDS) (14657)
  • Intensive Care and Critical Care Medicine (917)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (526)
  • Neurology (4957)
  • Nursing (263)
  • Nutrition (735)
  • Obstetrics and Gynecology (889)
  • Occupational and Environmental Health (797)
  • Oncology (2531)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1308)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (559)
  • Psychiatry and Clinical Psychology (4225)
  • Public and Global Health (7526)
  • Radiology and Imaging (1717)
  • Rehabilitation Medicine and Physical Therapy (1022)
  • Respiratory Medicine (982)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (73)
  • Transplantation (237)
  • Urology (206)